Table 4

Summary of the plausible target gene products with drug indications in systemic IMIDs

Associated SNPGene productAssociation results*Drugs†TargetsDisease indication‡
rs6659932IL12RB2 IIM, SLE, SScCanakinumabIL1BRA
AnakinraIL1R1RA
TofacitinibJAK kinasesRA
rs13389408GLS IIM, SLE, SScAzathioprinePPATRA, SLE
rs13101828DGKQ IIM, RA, SLE, SSc OrlistatLIPF
rs2736337FAM167A-BLK IIM, RA, SLE, SScNintedanibPDGFRBSSc
DasatinibBLK
ImatinibABL1
OsimertinibEGFR
VandetanibEPHA1
FingolimodS1PR1
BosutinibSRC
rs11085725TYK2 IIM, SLE, SScTofacitinibJAK kinasesRA
TocilizumabIL6RRA
Interferon Apha-2BIFNAR1
IdelalisibPIK3CD
RuxolitinibJAK1
  • *Based on our meta-analysis, diseases contributing to the observed association. The diseases where the association of this variant has never been reported before at genome-wide significance level are shown in boldface.

  • †Drugs from the OpenTarget platform with their corresponding target.

  • ‡Current indication of the reported drug. Non-immune mediated diseases were omitted.

  • IIM, idiopathic inflammatory myopathy; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; SSc, systemic sclerosis.